Solid Biosciences
SLDB
39 hedge funds and large institutions have $102M invested in Solid Biosciences in 2023 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 13 increasing their positions, 5 reducing their positions, and 5 closing their positions.
160% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 5
151% more capital invested
Capital invested by funds: $40.7M → $102M (+$61.5M)
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
8% more funds holding
Funds holding: 36 → 39 (+3)
1.84% more ownership
Funds ownership: 80.61% → 82.45% (+1.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$1.9M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$420K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$237K |
| 4 |
Two Sigma Investments
New York
|
+$119K |
| 5 |
Walleye Capital
New York
|
+$107K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$1.14M |
| 2 |
CCM
CAAS Capital Management
New York
|
-$162K |
| 3 |
BlackRock
New York
|
-$54.9K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$29.8K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$28.8K |
SLDB Hedge Fund Activity: Q4 2023 in Review
39 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Solid Biosciences (SLDB) for Q4 2023, worth a combined $102M — up 151% from $40.7M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new SLDB positions and 5 closed out — a net gain of 3 holders — while 13 added to existing stakes and 5 trimmed.
The largest buyer was Silverarc Capital Management, opening a new position worth an estimated $1.9M. The largest seller was Great Point Partners, exiting entirely with an estimated $1.14M sold.
- 39 institutional investors held Solid Biosciences (SLDB) as of Q4 2023, up from 36 in Q3 2023.
- Funds reported $102M of Solid Biosciences stock for Q4 2023, up 151% quarter-over-quarter.
- 8 funds opened new Solid Biosciences positions in Q4 2023 and 5 closed out, a net change of +3 holders.
- The largest Solid Biosciences buyer in Q4 2023 was Silverarc Capital Management, an estimated $1.9M added.
- The largest Solid Biosciences seller in Q4 2023 was Great Point Partners, an estimated $1.14M sold.
Based on aggregated 13F filings for Q4 2023.